2023
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad N, Bunck M, Benabbad I, Zhang X, investigators S, Abalos F, Manghi F, Zaidman C, Vico M, Aizenberg D, Costanzo P, Serra L, MacKinnon I, Hissa M, Vidotti M, Saraiva J, Alves B, Franco D, Moratto O, Murthy S, Goyal G, Yamasaki Y, Sato N, Inoue S, Asakura T, Shestakova M, Khaykina E, Troshina E, Vorokhobina N, Ametov A, Tu S, Yang C, Lee I, Huang C, Ou H, Freeman G, Machineni S, Klein K, Sultan S, Parsa A, Otero-Martinez J, Gonzalez A, Bhargava A, Brian S, Ince C, Plantholt S, Cole J, Lacour A, Vega D, de Souza J, Rohlf J, St. John R, Horowitz B, Audish H, Galindo R, Umpiperrez G, Ard J, Curtis B, Garvey W, Fraser N, Mandry J, Mohseni R, Mayfield R, Powell T, Vance C, Ong S, Lewy-Alterbaum A, Murray A, Al-Karadsheh A, Yacoub T, Roberts K, Fried D, Rosenstock J, Pulla B, Bode B, Frias J, Klaff L, Brazg R, Van J, Tan A, Briskin T, Rhee M, Chaicha-Brom T, Hartley P, Nunez L, Cortes-Maisonet G, Soucie G, Hsia S, Jones T. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet 2023, 402: 613-626. PMID: 37385275, DOI: 10.1016/s0140-6736(23)01200-x.Peer-Reviewed Original ResearchConceptsType 2 diabetesBody mass indexTreatment discontinuationAdverse eventsBodyweight reductionWeight managementGlucagon-like peptide-1 receptor agonistsInteractive web response systemPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptideComputer-generated random sequenceFrequent adverse eventsPlacebo-controlled trialSerious adverse eventsIncretin-based therapiesPhase 3 trialWeb response systemTreatment of obesityWeekly tirzepatideCoprimary endpointsRescue therapySafety endpointWeek 72Safety profileStudy treatmentTriple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff A, Kaplan L, Frías J, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman M. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal Of Medicine 2023, 389: 514-526. PMID: 37366315, DOI: 10.1056/nejmoa2301972.Peer-Reviewed Original ResearchConceptsBody weightPercentage changePlacebo groupEnd pointGlucagon-like peptide-1Glucose-dependent insulinotropic polypeptideLower starting doseWeight-related conditionsCommon adverse eventsPlacebo-controlled trialPrimary end pointSecondary end pointsBody mass indexTreatment of obesityDose-dependent increaseDose-response relationshipWeight reductionStarting doseAdverse eventsInsulinotropic polypeptideHeart ratePeptide-1Side effectsGlucagon receptorWeeksAssociation between specific types of parent stressors and fast-food consumption among parents and children
Bautista T, Fogelman N, Lartigue S, Silverman W, Jastreboff A, Sinha R. Association between specific types of parent stressors and fast-food consumption among parents and children. Eating Behaviors 2023, 49: 101724. PMID: 37054487, PMCID: PMC10247538, DOI: 10.1016/j.eatbeh.2023.101724.Peer-Reviewed Original ResearchConceptsHousehold chaosParent stressorsYoung childrenOnly significant predictorSignificant predictorsFast food consumptionStress interventionsSeparate regression modelsParentsSpecific typesYear oldsChildrenStressorsFast food intakeChildren's fast food consumptionPredictorsFinal modelHealthy foodsOldsBehaviorStressInterventionTurnBody mass indexFindings
2022
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal Of Medicine 2022, 387: 205-216. PMID: 35658024, DOI: 10.1056/nejmoa2206038.Peer-Reviewed Original ResearchConceptsBody weightTreatment discontinuationAdverse eventsGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptidePercentage changeDose escalation periodWeight-related complicationsCommon adverse eventsCoprimary end pointsBody mass indexSubstantial global morbidityTreatment of obesityMean percentage changePercentage of participantsMean body weightWeight reductionCardiometabolic measuresTreat populationPlacebo groupWeek 72Mean BMIWeekly dosesDose escalation
2021
Impact of Obesity on Heart Transplantation Outcomes
Chouairi F, Milner A, Sen S, Guha A, Stewart J, Jastreboff AM, Mori M, Clark KA, Miller PE, Fuery MA, Rogers JG, Notarianni A, Jacoby D, Maulion C, Anwer M, Geirsson A, Desai NR, Ahmad T, Mullan CW. Impact of Obesity on Heart Transplantation Outcomes. Journal Of The American Heart Association 2021, 10: e021346. PMID: 34854316, PMCID: PMC9075353, DOI: 10.1161/jaha.121.021346.Peer-Reviewed Original ResearchConceptsBody mass indexHigher BMI categoriesImpact of obesityHeart transplantation outcomesBMI categoriesTransplantation outcomesHeart transplantationHigher body mass indexAllocation system changeAdvanced heart failureOrgan Sharing databaseObese BMI categoriesVentricular assist deviceNew Organ ProcurementPosttransplant deathPosttransplantation deathPosttransplant mortalityBackground PatientsBMI 18.5Adult patientsCohort studyHeart failureHeart transplantSharing databaseWaitlist deathsLower synaptic density is associated with psychiatric and cognitive alterations in obesity
Asch RH, Holmes SE, Jastreboff AM, Potenza MN, Baldassarri SR, Carson RE, Pietrzak RH, Esterlis I. Lower synaptic density is associated with psychiatric and cognitive alterations in obesity. Neuropsychopharmacology 2021, 47: 543-552. PMID: 34294874, PMCID: PMC8674236, DOI: 10.1038/s41386-021-01111-5.Peer-Reviewed Original ResearchConceptsStress-related psychiatric disordersBody mass indexLower synaptic densitySynaptic densityPsychiatric disordersPsychiatric diagnosisOverweight/obesityNormal-weight individualsNormal-weight participantsSerious medical conditionPositron emission tomographyStress-related psychopathologyDorsolateral prefrontal cortexOverweight/Mass indexWeight participantsWeight individualsHealthy controlsTension/anxietyAssociated symptomatologyMedical conditionsIntervention development effortsObesityCognitive alterationsPsychiatric groupsObesity Is Associated With Intensive Care Use and Duration of ICU Stay but Not Mortality Among 3246 Patients Hospitalized With COVID-19
Kang Y, Brancale J, Athonvarangkul D, Alausa J, Subair L, Lipska K, Jastreboff A. Obesity Is Associated With Intensive Care Use and Duration of ICU Stay but Not Mortality Among 3246 Patients Hospitalized With COVID-19. Journal Of The Endocrine Society 2021, 5: a61-a62. PMCID: PMC8089233, DOI: 10.1210/jendso/bvab048.125.Peer-Reviewed Original ResearchIntensive care useAssociation of obesityICU careBody mass indexCare useHigh riskAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionPositive RT-PCR assaySyndrome coronavirus 2 infectionMultivariate logistic regression analysisCOVID-19Association of underweightCoronavirus 2 infectionDuration of ICUHypoxic respiratory failureNoninvasive ventilatory supportSevere coronavirus diseaseNormal-weight adultsLonger durationLogistic regression analysisSARS-CoV-2Health care systemRT-PCR assaysICU stay
2020
Body Mass Index and Age Effects on Brain 11β-Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study
Bini J, Bhatt S, Hillmer AT, Gallezot JD, Nabulsi N, Pracitto R, Labaree D, Kapinos M, Ropchan J, Matuskey D, Sherwin RS, Jastreboff AM, Carson RE, Cosgrove K, Huang Y. Body Mass Index and Age Effects on Brain 11β-Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study. Molecular Imaging And Biology 2020, 22: 1124-1131. PMID: 32133575, PMCID: PMC7351613, DOI: 10.1007/s11307-020-01490-z.Peer-Reviewed Original ResearchConceptsBody mass indexPositron emission tomographyDehydrogenase type 1Mass indexObese individualsEnzyme 11β-hydroxysteroid dehydrogenase type 1Whole brainType 1Higher body mass indexPositron emission tomography studyVT valuesSevere Alzheimer's diseaseEmission tomography studiesSteroid stress hormonesAge-associated increaseMean whole brainSignificant age-associated increaseRegional distribution volumesVisceral adiposityInsulin resistanceActive cortisolExcess cortisolInactive cortisoneMemory dysfunctionParietal lobe
2018
Preventing Childhood Obesity Through a Mindfulness-Based Parent Stress Intervention: A Randomized Pilot Study
Jastreboff AM, Chaplin TM, Finnie S, Savoye M, Stults-Kolehmainen M, Silverman WK, Sinha R. Preventing Childhood Obesity Through a Mindfulness-Based Parent Stress Intervention: A Randomized Pilot Study. The Journal Of Pediatrics 2018, 202: 136-142.e1. PMID: 30241766, PMCID: PMC6203652, DOI: 10.1016/j.jpeds.2018.07.011.Peer-Reviewed Original ResearchConceptsChildhood obesityChild body mass indexGroup interventionPhysical activity counselingRandomized pilot studyBody mass indexChildhood obesity riskControl group interventionEarly childhood obesityStress interventionsActivity counselingMass indexObesity riskPhysical activityTherapeutic mechanismObesityGroup attendanceRisk 2Pilot studyInterventionSignificant increaseLow-income parentsGreater improvementRiskParent-child dyads
2016
Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO
Gaiser EC, Gallezot JD, Worhunsky PD, Jastreboff AM, Pittman B, Kantrovitz L, Angarita GA, Cosgrove KP, Potenza MN, Malison RT, Carson RE, Matuskey D. Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO. Neuropsychopharmacology 2016, 41: 3042-3050. PMID: 27374277, PMCID: PMC5101552, DOI: 10.1038/npp.2016.115.Peer-Reviewed Original ResearchConceptsBody mass indexVentral striatumObese individualsD2/3R availabilityOB individualsReward regionsSubstantia nigra/ventral tegmental areaDopamine D2/3 receptor availabilityNormal-weight individualsTreatment of obesityVentral tegmental areaNovel pharmacologic targetsD2/3 receptor availabilitySN/VTAAgonist tracersOverweight cohortMass indexWeight individualsTegmental areaBrain reward regionsAntagonist tracersPharmacologic targetReceptor availabilitySecondary analysisNW individualsUtility of Psychological Screening of Young Adults with Type 1 Diabetes Transitioning to Adult Providers
Quinn SM, Ambrosino JM, Doyle EA, Weyman K, Tamborlane WV, Jastreboff AM. Utility of Psychological Screening of Young Adults with Type 1 Diabetes Transitioning to Adult Providers. Endocrine Practice 2016, 22: 1104-1110. PMID: 27295017, DOI: 10.4158/ep151190.or.Peer-Reviewed Original ResearchConceptsChart reviewEating Problem SurveyDiabetes distressAdditional patientsYoung adultsDepressive symptomsProblem SurveyPoor glycemic controlDiabetes Eating Problem SurveyBody mass indexDiabetes Distress ScalePatient Health QuestionnaireType 1 diabetesTransition clinicGlycemic controlMass indexPHQ-8Formal screeningAdult providersGlycated hemoglobinSymptomatic depressionAdult careHealth QuestionnaireMetabolic controlPatients
2014
Blunted striatal responses to favorite-food cues in smokers
Jastreboff AM, Sinha R, Lacadie CM, Balodis IM, Sherwin R, Potenza MN. Blunted striatal responses to favorite-food cues in smokers. Drug And Alcohol Dependence 2014, 146: 103-106. PMID: 25444233, PMCID: PMC4272899, DOI: 10.1016/j.drugalcdep.2014.09.006.Peer-Reviewed Original ResearchConceptsFavorite-food cuesNeural responsesNeutral-relaxing conditionsBody mass indexCue exposureBrain mechanismsRewarding stimuliBrain responsesStriatal responsesCuesDiminished activationLower body mass indexLean body massSmoking cessationMass indexSmoking statusFMRIInsulaSmokersWeight gainStimuliRatingsAudiotapesCaudateBody massSex differences in the association between dietary restraint, insulin resistance and obesity
Jastreboff AM, Gaiser EC, Gu P, Sinha R. Sex differences in the association between dietary restraint, insulin resistance and obesity. Eating Behaviors 2014, 15: 286-290. PMID: 24854820, PMCID: PMC4032476, DOI: 10.1016/j.eatbeh.2014.03.008.Peer-Reviewed Original ResearchConceptsBody mass indexInsulin resistanceMass indexRestrained eatingHomeostatic model assessmentSex differencesObese weight categoriesEating Behavior QuestionnaireEventual weight gainDutch Eating Behavior QuestionnaireHOMA-IRPlasma insulinObservational studyModel assessmentAbstractTextWeight categoriesWeight gainDietary restraintLarge community sampleFood consumptionWomenMenAIMSCommunity sampleBehavior Questionnaire
2010
Body Mass Index, Metabolic Factors, and Striatal Activation During Stressful and Neutral-Relaxing States: An fMRI Study
Jastreboff AM, Potenza MN, Lacadie C, Hong KA, Sherwin RS, Sinha R. Body Mass Index, Metabolic Factors, and Striatal Activation During Stressful and Neutral-Relaxing States: An fMRI Study. Neuropsychopharmacology 2010, 36: 627-637. PMID: 21048702, PMCID: PMC3055687, DOI: 10.1038/npp.2010.194.Peer-Reviewed Original ResearchConceptsMetabolic factorsFunctional magnetic resonance imagingOB individualsOW/OB individualsVentral striatumVS activationBody mass index statusCortico-limbic regionsNon-homeostatic feedingBody mass indexNormal-weight individualsMagnetic resonance imagingAlcohol cue exposureMass indexObese individualsPlasma glucoseStriatal dysfunctionWeight individualsIndex statusPersonalized stressResonance imagingSignificant associationNW individualsCue exposureMetabolic changes